Adult: <60 kg: 30 mg 12 hrly; ≥60 kg: 40 mg 12 hrly. Child: Birth to 13 days 0.5 mg/kg 12 hrly; ≥14 days <30 kg: 1 mg/kg 12 hrly; ≥30 kg: Same as adult dose.
<60 kg: 15 mg 24 hrly; ≥60 kg: 20 mg 24 hrly.
<60 kg: 15 mg 12
hrly; ≥60 kg: 20 mg 12 hrly.
May be taken with or without food.
Oral soln: Reconstitute w/ purified water to provide a soln containing 1 mg/mL.
Hypersensitivity to stavudine. Lactation.
Patient w/ hepatomegaly, hepatitis or other risk factors for liver disease (esp obese women); pre-existing bone marrow suppression; history of peripheral neuropathy; history of or risk factors for pancreatitis. Renal or hepatic impairment. Pregnancy.
This drug may cause dizziness and/or somnolence, if affected, do not drive or operate machinery.
Monitor LFTs, renal function tests, viral load, CD4 count.
Symptoms: Peripheral neuropathy and hepatic toxicity. Management: Supportive and symptomatic treatment.
Increased risk of pancreatitis, peripheral neuropathy and hepatotoxicity in combination w/ didanosine and hydroxycarbamide. Risk of hepatic decompensation w/ interferon and ribavirin. Risk of peripheral neuropathy w/ isoniazid. Zidovudine may decrease the phosphorylation of stavudine to its active triphosphate form. Doxorubicin and ribavirin may inhibit stavudine activation.
Food delays but does not reduce absorption.
Description: Stavudine, a thymidine analogue, is converted intracellularly to the active metabolite stavudine triphosphate which inhibits HIV reverse transcriptase by competing w/ the natural substrate, thymidine triphosphate. It also inhibits viral DNA synthesis by causing DNA chain termination. Pharmacokinetics: Absorption: Rapidly absorbed from the GI tract. Bioavailability: Approx 86%. Time to peak plasma concentration: W/in 1 hr. Distribution: Distributed into CSF. Crosses the blood-brain barrier and enters breast milk. Volume of distribution: 46 L. Metabolism: Undergoes intracellular phosphorylation by thymidine kinase to the active metabolite, stavudine triphosphate. Excretion: Via urine (95%, 74% as unchanged drug) and faeces (3%, 62% as unchanged drug). Elimination half-life: Approx 1-1.5 hr.
Store at 25°C. Reconstituted soln: Store between 2-8°C.
J05AF04 - stavudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Anon. Stavudine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/02/2016 .Buckingham R (ed). Stavudine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2016 .Joint Formulary Committee. Stavudine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2016 .McEvoy GK, Snow EK, Miller J et al (eds). Stavudine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 10/02/2016 .Stavudine Capsule (Mylan Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/02/2016 .